Jiao Jiao Li – VJRegenMed

Exploring stem cell-based therapies in osteoarthritis

Simon Ng — Fri, 21 Jan 2022 11:14:51 +0000

Osteoarthritis (OA) is a chronic illness currently with no cure, and patients with OA often have comorbidities such as diabetes and cardiovascular diseases. Jiao Jiao Li, PhD, University of Technology Sydney, Sydney, Australia, provides an overview of the influence on stem cells in osteoarthritis and how stem cell-based therapies have not been effective in OA. Research investigating the interactions between mesenchymal stem cells (MSCs) and arthritic cells revealed that MSCs had a short-term effect on arthritic cells, but arthritic cells induced inflammatory markers in MSCs and prevented them from differentiating into cartilage tissue. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Tackling issues in regenerating cartilage and tendons

Simon Ng — Wed, 19 Jan 2022 13:01:31 +0000

Jiao Jiao Li, PhD, University of Technology Sydney, Sydney, Australia, comments on difficulties in regenerating cartilage, tendons and ligaments. As the aforementioned tissues are interface tissue connecting bone to muscles and other tissues, the complex structure makes regenerating cartilage and tendons difficult compared to bone. The tissues are additionally avascular and have no neural links unlike bones, which limit their regenerative capacity. Dr Li also emphasizes the need for a multidisciplinary approach and the adoption of novel technologies such as artificial intelligence to optimize the conditions to regrow cartilage and tendons. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

The role of bioactive ceramics in vascularized bone regeneration

Simon Ng — Mon, 17 Jan 2022 18:10:26 +0000

Jiao Jiao Li, PhD, University of Technology Sydney, Sydney, Australia, discusses research on regenerating vascularized bone with bioactive ceramics. Current challenges in the field include developing load-bearing scaffolds that can interact with bone cells and are porous. Therapies that encourage vascularization in the bone are necessary due to the metabolic demands of bones, and advances in 3D bioprinting have enabled research into bioactive ceramics. Nanoparticles additionally represent encouraging solutions to musculoskeletal conditions including osteoarthritis. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Challenges with developing regenerative therapies for musculoskeletal disorders

Simon Ng — Thu, 06 Jan 2022 16:53:11 +0000

Jiao Jiao Li, PhD, University of Technology Sydney, Sydney, Australia, describes issues developing regenerative therapies for musculoskeletal disorders. Finding suitable materials with the correct properties for bioprinting remains a major hurdle, and whilst induced pluripotent stem cells (iPSCs) have shown promise in cellular therapies, more research is required for successful clinical adaptation. Dr Li additionally highlights how regulatory authorities may have difficulties classifying novel products such as extracellular vesicles (EVs), due to their complexity, as well as problems relating to large scale manufacturing of tissue-engineered therapies. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

TERMIS 2021 highlights: Extracellular vesicles

Simon Ng — Thu, 06 Jan 2022 16:53:10 +0000

Jiao Jiao Li, PhD, University of Technology Sydney, Sydney, Australia, emphasizes the need to focus on extracellular vesicles (EVs) at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021). She highlights the potential research that will be carried out in the field of EVs, as well as the incorporation of technologies such as biosensors and artificial intelligence in the development of tissue-engineered therapies. This interview took place at TERMIS 2021.